114 related articles for article (PubMed ID: 38135187)
1. Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study.
Chuong MD; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Raphael Pfeffer M; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Jitendra Parikh P
Radiother Oncol; 2024 Feb; 191():110064. PubMed ID: 38135187
[TBL] [Abstract][Full Text] [Related]
2. A Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
Parikh PJ; Lee P; Low DA; Kim J; Mittauer KE; Bassetti MF; Glide-Hurst CK; Raldow AC; Yang Y; Portelance L; Padgett KR; Zaki B; Zhang R; Kim H; Henke LE; Price AT; Mancias JD; Williams CL; Ng J; Pennell R; Pfeffer MR; Levin D; Mueller AC; Mooney KE; Kelly P; Shah AP; Boldrini L; Placidi L; Fuss M; Chuong MD
Int J Radiat Oncol Biol Phys; 2023 Nov; 117(4):799-808. PubMed ID: 37210048
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.
Bordeau K; Michalet M; Keskes A; Valdenaire S; Debuire P; Cantaloube M; Cabaillé M; Portales F; Draghici R; Ychou M; Assenat E; Mazard T; Samalin E; Gauthier L; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612004
[TBL] [Abstract][Full Text] [Related]
4. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART).
Bryant JM; Palm RF; Herrera R; Rubens M; Hoffe SE; Kim DW; Kaiser A; Ucar A; Fleming J; De Zarraga F; Hodul P; Aparo S; Asbun H; Malafa M; Jimenez R; Denbo J; Frakes JM; Chuong MD
Cancer Control; 2023; 30():10732748221150228. PubMed ID: 36598464
[TBL] [Abstract][Full Text] [Related]
5. Induction Chemotherapy and Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy for Inoperable Pancreas Cancer.
Chuong MD; Herrera R; Kaiser A; Rubens M; Romaguera T; Alvarez D; Kotecha R; Hall MD; McCulloch J; Ucar A; DeZarraga F; Aparo S; Joseph S; Asbun H; Jimenez R; Narayanan G; Gutierrez AN; Mittauer KE
Front Oncol; 2022; 12():888462. PubMed ID: 35814383
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
Front Oncol; 2022; 12():842402. PubMed ID: 35356227
[TBL] [Abstract][Full Text] [Related]
7. Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided Radiation Therapy With On-Table Adaptive Replanning and Elective Nodal Irradiation for Inoperable Pancreas Cancer.
Chuong MD; Bryant J; Mittauer KE; Hall M; Kotecha R; Alvarez D; Romaguera T; Rubens M; Adamson S; Godley A; Mishra V; Luciani G; Gutierrez AN
Pract Radiat Oncol; 2021; 11(2):134-147. PubMed ID: 32947042
[TBL] [Abstract][Full Text] [Related]
8. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma.
Webking S; Sandoval ML; Chuong MD; Ucar A; Aparo S; De Zarraga F; Sahin I; Biachi T; Kim DW; Hoffe SE; Frakes JM; Palm RF
Cancer Control; 2023; 30():10732748231219069. PubMed ID: 38038261
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic MR-guided online adaptive radiotherapy reirradiation (SMART reRT) for locally recurrent pancreatic adenocarcinoma: A case report.
Doty DG; Chuong MD; Gomez AG; Bryant J; Contreras J; Romaguera T; Alvarez D; Kotecha R; Mehta MP; Gutierrez AN; Mittauer KE
Med Dosim; 2021 Winter; 46(4):384-388. PubMed ID: 34120803
[TBL] [Abstract][Full Text] [Related]
12. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
[TBL] [Abstract][Full Text] [Related]
13. Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.
Henke LE; Stanley JA; Robinson C; Srivastava A; Contreras JA; Curcuru A; Green OL; Massad LS; Kuroki L; Fuh K; Hagemann A; Mutch D; McCourt C; Thaker P; Powell M; Markovina S; Grigsby PW; Schwarz JK; Chundury A
Int J Radiat Oncol Biol Phys; 2022 Feb; 112(2):379-389. PubMed ID: 34474109
[TBL] [Abstract][Full Text] [Related]
14. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
15. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART).
Bryant JM; Palm RF; Liveringhouse C; Boyer E; Hodul P; Malafa M; Denbo J; Kim D; Carballido E; Fleming JB; Hoffe S; Frakes J
Adv Radiat Oncol; 2022; 7(6):101045. PubMed ID: 36420193
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma.
Paiella S; Malleo G; Simoni N; Micera R; Guariglia S; Cavedon C; Marchegiani G; Esposito A; Landoni L; Casetti L; Tuveri M; Milella M; Secchettin E; Manzini G; Bovo C; De Pastena M; Fontana M; Salvia R; Mazzarotto R; Bassi C
BMC Cancer; 2021 Feb; 21(1):165. PubMed ID: 33593311
[TBL] [Abstract][Full Text] [Related]
17. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
[TBL] [Abstract][Full Text] [Related]
18. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ
Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Esnaola NF; Chaudhary UB; O'Brien P; Garrett-Mayer E; Camp ER; Thomas MB; Cole DJ; Montero AJ; Hoffman BJ; Romagnuolo J; Orwat KP; Marshall DT
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):837-44. PubMed ID: 24606850
[TBL] [Abstract][Full Text] [Related]
20. Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer.
Kharofa J; Mierzwa M; Olowokure O; Sussman J; Latif T; Gupta A; Xie C; Patel S; Esslinger H; Mcgill B; Wolf E; Ahmad SA
Am J Clin Oncol; 2019 Mar; 42(3):247-252. PubMed ID: 30724781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
